News | January 26, 2024
Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The new campus has been designed as an employee-centred experience and ecosystem zone
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Subscribe To Our Newsletter & Stay Updated
